{"contentid": 488494, "importid": NaN, "name": "Global medicine spending to reach $1.6 trillion in 2025", "introduction": "Global spending on medicines - using invoice price levels - is expected to grow at a 3%-6% compound annual growth rate (CAGR) through 2025 to reach a value of about $1.6 trillion by 2025, excluding spending of COVID-19 vaccines, according to a new research report.", "content": "<p>Global spending on medicines - using invoice price levels - is expected to grow at a 3%-6% compound annual growth rate (CAGR) through 2025 to reach a value of about $1.6 trillion by 2025, excluding spending of COVID-19 vaccines, according to a new research report - The Global Spending and Usage of Medicines &ndash; which has been released today by the IQVIA Institute for Human Data Science.</p>\n<p>The total cumulative spending on COVID-19 vaccines through 2025 is projected to be $157 billion, largely focused on the initial wave of vaccinations to be completed by 2022. In subsequent years, booster shots are expected to be required on a biannual basis as the durability of immunity and the continued emergence of viral variants make an endemic virus the most likely outcome.</p>\n<p>&ldquo;While the pandemic has been extremely disruptive, the pre-pandemic forces of medicine use and spending remain significant drivers of the outlook, and these forces have only been modestly impacted by the immediate effects of COVID-19,&rdquo; said Murray Aitken, IQVIA senior vice president and executive director of the IQVIA Institute for Human Data Science. &ldquo;The success of countries around the world in implementing a global vaccination program - unprecedented in speed and scope - will be key to the outlook for all medicine use through 2025 and beyond,&rdquo; he noted.</p>\n<h2><strong>Highlights</strong></h2>\n<ul>\n<li>The global medicine market - using invoice price levels - is expected to grow at 3%-6% CAGR through 2025;</li>\n<li>The total cumulative spending on COVID-19 vaccines through 2025 is projected to be $157 billion;&nbsp;</li>\n<li>Global medicine spending will be lifted by stronger pharmerging market growth through 2025 and offset by slower growth in developed markets caused by losses of exclusivity for original brands;</li>\n<li>Savings from biosimilars will reach an estimated $285 billion over the next five years;&nbsp;</li>\n<li>The two leading global therapy areas - oncology and immunology - are forecast to grow 9%-12% CAGR through 2025, lifted by significant increases in new treatments and medicine use;</li>\n<li>On a net price basis, the US market is forecast to grow 0%-3% CAGR over the next five years, down from 3% CAGR for the past five years;</li>\n<li>As the third largest global market, Japan will have flat-to-declining medicine spending as a result of the continued biennial price cut policy but see rising patent-protected original brand spending coinciding with policies to encourage a shift to generics for older medicines; and</li>\n<li>Spending in Europe is expected to increase 2%-5% CAGR or a total of $35 billion over the five years to 2025.</li>\n</ul>\n<p>The full version of the report, including a detailed description of the methodology, is available at <a href=\"http://www.iqviainstitute.org\">www.IQVIAInstitute.org</a>. The study was produced independently as a public service, without industry or government funding.</p>\n<p>&nbsp;</p>", "date": "2021-04-29 12:47:00", "meta_title": "Global medicine spending to reach $1.6 trillion in 2025", "meta_keywords": "Medicines, Spending, Global, IQVIA", "meta_description": "Global medicine spending to reach $1.6 trillion in 2025", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-29 12:22:38", "updated": "2021-04-29 12:47:30", "access": NaN, "url": "https://www.thepharmaletter.com/article/global-medicine-spending-to-reach-1-6-trillion-in-2025", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "iqvia_large.png", "image2id": "iqvia_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "All therapy areas, Infectious diseases, Vaccines", "topic_tag": "Coronavirus, Focus On, Markets & Marketing", "geography_tag": NaN, "company_tag": "IQVIA INC.", "drug_tag": NaN, "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-29 12:47:00"}